Watson Health And Pfizer Partner To Harness Big Data For Drug Discovery
The advanced data analytics provider IBM Watson Health has signed its first big pharma partner – Pfizer – for a new drug discovery tool, with a focus on immuno-oncology.
You may also be interested in...
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.